Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:IRWD

Ironwood Pharmaceuticals Q3 2026 Earnings Date & Estimates

Ironwood Pharmaceuticals logo
$3.60 +0.01 (+0.28%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$3.58 -0.02 (-0.69%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ironwood Pharmaceuticals is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Ironwood Pharmaceuticals in Q3 2026

Ironwood Pharmaceuticals is expected to post earnings of $0.3233 per share on revenue of $119.99 million. In the same quarter a year earlier Ironwood Pharmaceuticals reported $0.24 per share on revenue of $122.06 million. Ironwood Pharmaceuticals last reported on August 6, 2026, posting $0.31 per share and missing the $0.32 consensus estimate. Ironwood Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.3233
Expected Revenue
$119.99 million
Prior-Year EPS
$0.24
Prior-Year Revenue
$122.06 million
Expected EPS Growth
+34.7%
Expected Revenue Growth
-1.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.31 (Missed by -$0.01)
Last Quarter Revenue
$113.04 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Ironwood Pharmaceuticals Q3 2026 Earnings FAQ

Ironwood Pharmaceuticals (NASDAQ:IRWD) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Ironwood Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Ironwood Pharmaceuticals to post earnings of $0.3233 per share for Q3 2026.

The consensus revenue estimate for Ironwood Pharmaceuticals is $119.99 million for Q3 2026.

Ironwood Pharmaceuticals Earnings Headlines

Ironwood Pharmaceuticals, Inc. (IRWD) - What Are Investment Firms Saying About This Stock?
October 13 at 4:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114135
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy
October 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952469-ironwood-pharmaceuticals-the-stock-is-a-call-on-the-second-apraglutide-trial-buy?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
 |  Chaikin Analytics (Ad)
Ironwood Pharmaceuticals, Inc. (IRWD)
September 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/IRWD/latest-news/
Ironwood: Medicare Is Not The Problem I Thought It Was
September 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945504-ironwood-medicare-is-not-the-problem-i-thought-it-was
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260903998988/en/ironwood-pharmaceuticals-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference/
See More Ironwood Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ:IRWD) is a gastrointestinal-focused biopharmaceutical company that discovers, develops, and commercializes medicines for gastrointestinal diseases. The company concentrates on conditions affecting the digestive system, including disorders with substantial unmet medical needs.

Ironwood’s principal commercial product is LINZESS (linaclotide), a prescription treatment for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. In the United States, LINZESS is marketed through a collaboration with AbbVie, while it is marketed in many international markets under the name CONSTELLA through a collaboration with the healthcare business of AstraZeneca and other regional partners.

Founded in 1998 and headquartered in Boston, Massachusetts, Ironwood has expanded its development activities through internal research, partnerships, and acquisitions. The company’s pipeline has included additional therapies for gastrointestinal and related disorders, including programs obtained through its acquisition of VectivBio. Ironwood’s products and development programs serve patients in the United States and selected international markets through its commercial operations and collaboration network. Tom McCourt serves as the company’s chief executive officer.

View Ironwood Pharmaceuticals Profile
Earnings Tools